

Agilent SampliQ OPT Solid Phase Extraction Sorbent in the Clean-up of Alkaloids in Goldenseal by HPLC-DAD

Application Note

Environmental

Authors

Janes Mokgadi, Lesego C. Mmualefe,
and Nelson Torto

Department of Chemistry,
Rhodes University,

P. O. Box 94, Grahamstown 6140,
South Africa

Abstract

Sample clean-up of alkaloids of Goldenseal commercial products (hydrastine and berberine) was achieved by solid phase extraction employing Agilent's SampliQ Optimized Polymer Technology (OPT) sorbents. Separation of the products with a 0.1% phosphoric acid/methanol mobile phase was carried out on an Agilent 1200 series HPLC coupled with a diode array detector (DAD) on an Agilent ZORBAX Eclipse Plus C18 column (4.5 mm × 75 mm × 3.5 μm) using gradient elution with a 6 min total run time. The recovery for hydrastine ranged from 101% to 106% (n = 8) while that of berberine ranged from 71% to 82%, (n = 8), each with % relative standard deviation (RSD) of less than 1. The limits of detection and quantification for hydrastine were 0.50 and 1.65 μg/mL respectively while those of berberine were 0.47 and 1.55 μg/mL, respectively. Goldenseal sample from Willow contained 17 μg/mL hydrastine and 35 μg/mL berberine while Goldenseal sample from Solga contained 6 μg/mL hydrastine and 12 μg/mL berberine.



Agilent Technologies

Introduction

Goldenseal (*Hydrastis canadensis* L.) is a perennial herb in the Ranunculaceae family native to southeastern Canada and northeastern United States of America (USA) and is amongst the oldest herbal medicinal plants, most commonly employed in the Traditional Chinese Medicines (TCM) [1, 2]. The biological activities of Goldenseal are associated with the isoquinoline alkaloids hydrastine and berberine (see structures in Figure 1) even though the plant also contains other alkaloids including hydrastinine, tetrahydroberberine and canadine [2]. Goldenseal has been used for the treatment of infections, inflammation and as an immune system booster [3]. However, due to the imminence of new directives and legislation intended to regulate both the herbal and nutraceutical industries, there is a growing need for robust and highly sensitive analytical methods involving sample handling, which includes sampling, clean up and pre-concentration.

Sample handling is considered to be a fundamental step in the analytical procedure because it helps to achieve the low detection limits set by regulatory authorities [4]. Solid phase extraction (SPE) is one of the most popular sample clean up techniques used in sample handling prior to analysis of environmental, food, pharmaceutical, and biological samples by high-performance liquid chromatography (HPLC) or gas chromatography (GC). SPE has many advantages over traditional liquid-liquid extraction, such as the use of minimal amounts of organic solvent, ease of automation, lower cost, and reduced volumes of toxic residues [5]. In recent years, many reports have described the development of new SPE materials, for example mixed-mode sorbents as well as restricted access sorbents, immunoaffinity extraction sorbents, molecularly imprinted polymers, and conductive polymers [6, 7, 8].

This application note presents a method that has been optimized for SPE of hydrastine and berberine in Goldenseal employing Agilent SampliQ Optimized Polymer Technology (OPT) cartridges, which utilize polymeric sorbents, with significant reduction of matrix interferences, resulting in improved analysis.




Figure 1. Structures of hydrastine and berberine.

Experimental

Materials and Chemicals

Berberine hydrochloride and hydrastine hydrochloride standards were purchased from Sigma-Aldrich (Saint Louis, MO, USA). Phosphoric acid and potassium hydroxide were purchased from Merck Chemicals (Gauteng, South Africa) while HPLC grade methanol was purchased from Merck KGaA (Darmstadt, Germany). Potassium dihydrogen phosphate was from Saarchem Analytic (Krugersdorp, South Africa). Goldenseal capsules (Golden Seal Capsules, Willow Products, Port Elizabeth, South Africa and Solga Full Potency Herbs, Solgar Corporation, Leonia, NJ, USA) were purchased from a local herbal store in Grahamstown, South Africa. SPE cartridges were Agilent SampliQ OPT, 1 mL/30 mg tubes. Analysis was performed on an Agilent 1200 series gradient HPLC coupled with a diode array detector (DAD). The analytical column was an Agilent ZORBAX Eclipse Plus C18 column (4.5 mm × 75 mm × 3.5 μm).

Preparation of Stock and Working Solutions

The stock solution of hydrastine and berberine, 1000 μg/mL each, were prepared in methanol and stored at 4 °C when not used. All other standard solutions were prepared from the stock solution as required.

Sample Preparation

The contents of the capsules were first homogenized. Then, 200 mg of the homogenized sample were mixed with 50 mL of methanol and then stirred with a magnetic stirrer for 1 h, resulting in a suspension with undissolved particulates floating in it. The extracts were then filtered using a hydrophobic polyvinylidene fluoride (PVDF) 0.45 μm Millipore Millex – HV membrane filter (Billerica, MA, USA). The methanolic extracts were diluted 1:3 with water and the pH adjusted to ~ 7 with 0.01 M potassium hydroxide.

Separation

A 5 μL aliquot of a hydrastine-berberine mixed standard (50 μg/mL of each) was injected into the HPLC column to optimize their separation. The HPLC conditions are as outlined in Table 1 below:

Table 1. HPLC Conditions

Column	Agilent ZORBAX Eclipse Rapid Resolution Plus C18, column, 4.6 mm × 75 mm, 3.5 μm (p/n 959933-902)			
Flow rate	1 mL/min			
Injection volume	5 μL			
Column temperature	35 °C			
Mobile phase	A: 0.1% Phosphoric acid B: Methanol			
Run time	6 min			
Post time	2 min			
Gradient	Time	0	0.5	5
	%B	20	20	50

SPE Procedure

A systematic study of a series of conditioning, loading, washing and elution solvents was performed. The procedure was optimized by evaluating the isolation of hydrastine and berberine from a standard solution. Figure 2 shows the results of the optimization process.




Figure 2. SPE procedure for cleaning alkaloids in Goldenseal using SampliQ OPT sorbent.

Results and Discussion

Separation and SPE Clean Up

Although the hydrastine and berberine standards could be separated isocratically, the initial analysis time was rather long (15 min) so gradient elution was essential to reduce the run time. Using the optimized HPLC conditions outlined in Table 1, Figure 3 shows the well-separated symmetrical peaks for the hydrastine and berberine standards in just over 4.5 minutes. A blank carried through the entire procedure showed no discernible peaks in the baseline. Next, a simple filtered extract from the Willow Goldenseal sample was injected prior to (Figure 4a) and after sample cleanup using the SPE procedure (Figure 4b). Note the decrease in the number of small peaks in Figure 4b indicating that the SPE treatment removed a number of potentially interfering species. A second sample of Goldenseal from Willow was spiked and treated in a similar manner to confirm the peak assignments. The results in Figure 5a and 5b showed that the peak intensity was increased and interfering peaks were significantly reduced.




Figure 3. Chromatogram of hydrastine (120 $\mu\text{g}/\text{mL}$) and berberine (100 $\mu\text{g}/\text{mL}$) standard mix.




Figure 4. Chromatograms of Goldenseal samples before (a) and after (b) clean up.




Figure 5. Chromatograms of Goldenseal Willow spiked samples (hydrastine and berberine, 60 and 40 µg/mL, respectively) before (a) and after (b) clean-up with SampliQ OPT sorbent.

Recovery and Reproducibility

The recoveries and reproducibility of berberine and hydrastine were evaluated by analyzing eight replicates of the commercial sample (Goldenseal Willow capsules) that were spiked at three different concentration levels of hydrastine and berberine within a day and then introduced to the SPE procedure. The background level of the spiked samples was determined for each concentration before clean up. Recovery was calculated by comparison of peak areas of unclean to those of the cleaned extracts. The recovery and reproducibility values for berberine and hydrastine are as outlined in the Table 2 below. The % RSDs were all less than 1, quite acceptable for an SPE cleanup and HPLC analysis procedure.

Table 2. Recovery and Reproducibility Data for the Two Alkaloids Standards

Compound	Level spiked (µg/mL) n=8	% Recovery	% RSD
Hydrastine	40	101	0.16
	60	102	0.56
	100	106	0.75
Berberine	10	71	0.17
	40	71	0.40
	80	82	0.32

Calibration Curves

The calibration curves were determined by preparing appropriate concentrations in methanol from berberine and hydrastine stock solutions and injecting directly into the HPLC column without SPE procedure. The method was found to be linear in the concentration ranges of 0–120 µg/mL for hydrastine and 0–100 µg/mL of berberine each with r^2 of 0.9994.




Figure 6. Calibration curves of (a) hydrastine and (b) berberine.

Linearity of the SPE Method

Linearity was studied on the SampliQ OPT sorbent by spiking sample extracts with increasing concentrations of hydrastine and berberine followed by SPE clean-up. At concentrations higher than 200 µg/mL for berberine, linearity was no longer observed (Figure 7). This is due to the fact that the SPE sorbent was overloaded and could no longer retain the alkaloid berberine. Most of the sample was lost at the washing step while some was lost even at the loading stage. For hydrastine, SampliQ OPT sorbent showed linearity for up to 500 µg/mL.




Figure 7. Linearity of (a) hydrastine and (b) berberine at higher concentrations.

Analysis of the Commercial Product

The method described was successfully applied to the analysis of the commercial products, Goldenseal capsules from Willow and Solga. Both products contained low but quantifiable amounts of the alkaloids as indicated in Table 3.

Table 3. Concentrations of hydrastine and berberine in Commercial Samples

	Concentration (µg/mL)	
	Hydrastine	Berberine
Willow	17	34
Solga	6	12

Limit of Detection and Limit of Quantification

The limits of detection were calculated using the intercept, y_B , and the standard error of the regression line, s_B at 3 times the standard error and LOD values were calculated using equations 1 and 2 [9,10].

$$y_{LOD} = y_B + 3s_B \quad (\text{Eqn 1})$$

$$LOD = (y_{LOD} - y_B)/m \quad \text{where } m = \text{gradient} \quad (\text{Eqn 2})$$

LOQ values were calculated using the same method as in equations 1 and 2, but using 10 times the standard error of regression line, (equations 3 and 4).

$$y_{LOQ} = y_B + 10s_B \quad (\text{Eqn 3})$$

$$LOQ = (y_{LOQ} - y_B)/m \quad (\text{Eqn 4})$$

The limit of detection and quantification for hydrastine were found to be 0.50 and 1.65 µg/mL, respectively, while that of berberine was 0.47 and 1.55 µg/mL, respectively.

Conclusions

Agilent SampliQ OPT cartridges achieved effective sample clean up of the TCM Goldenseal for the separation and analysis of hydrastine and berberine. The results demonstrated that the method was reproducible and reliable with good recoveries (101% to 106% for hydrastine and 71% to 86% for berberine) at $n = 8$ and RSD less than 1%. The limits of detection and quantification for hydrastine were 0.50 and 1.65 µg/mL respectively while those of berberine were 0.47 and 1.55 µg/mL respectively. Goldenseal sample from Willow contained 17 µg/mL hydrastine and 35 µg/mL berberine while Goldenseal sample from Solga contained 6 µg/mL hydrastine and 12 µg/mL berberine.

References

1. P. N. Brown and M. C. Roman, *JAOAC Int*, 91 (4) (2008), 694-701
2. M. Govindan and G. Govindan, *Fitoterapia*, 71 (2000), 232-235
3. L. Tong, Y. Liang, J. Song L. Xie, G. J. Wang, X. D. Lui, *J of Pharm Biomed Anal*, 40 (2006), 1218-1224.
4. L. Mmualefe, N. Torto, P. Huntsman-Mapila, B. Mbongwe, *Microchemical Journal* 91 (2009), 239-244.
5. L. F. C. Melo, C. H. Collins, I. C. S. F. Jardim, *Journal of Chromatography A*, 1032 (2004), 51-58
6. M. S. Landis, *J. of Pharm. Biomed. Anal.* 44 (2007), 1029-1039
7. K. Bielicka-Daszkiwicz, A. Voelkel, M. Szejner and J. Osypiul, *Chemosphere*, 62 (2006) 890-898.
8. M. C. Hennion, *J. of Chromatography A*, 856 (1999), 3-54
9. F. Deng and S. W. Zito, *J of Chhrom A*, 986 (2003) 121-127
10. M. A. Alabdalla, *Journal of Clinical Forensic Medicine*, 12 (2005) 310-315

For More Information

For more information on our products and services, visit our Web site at www.agilent.com/chem.

www.agilent.com/chem

Agilent shall not be liable for errors contained herein or for incidental or consequential damages in connection with the furnishing, performance, or use of this material.

Information, descriptions, and specifications in this publication are subject to change without notice.

© Agilent Technologies, Inc., 2009
Printed in the USA
June 30, 2009
5990-4188EN



Agilent Technologies